What are the Pan‑Asian guidelines for managing triple‑negative breast cancer, including neoadjuvant chemotherapy, surgery, whole‑breast irradiation, and systemic therapy?

Pan-Asian Guidelines for Triple-Negative Breast Cancer (TNBC)

For triple-negative breast cancer, the Pan-Asian adapted ESMO guidelines recommend neoadjuvant chemotherapy with sequential anthracyclines and taxanes for tumors >2 cm, with consideration of adding platinum compounds, followed by surgery, whole-breast irradiation, and adjuvant capecitabine for high-risk patients who do not achieve pathological complete response (pCR). 1

Neoadjuvant Chemotherapy Approach

Indications for Neoadjuvant Therapy

• Primary systemic therapy (PST) should be used to reduce surgical extent in locally advanced and large operable cancers, particularly when mastectomy would otherwise be required 1
• Consider neoadjuvant therapy for all TNBC tumors >2 cm where chemotherapy is deemed necessary 1
• Neoadjuvant therapy is preferred over adjuvant therapy as it allows for response assessment and prognostic information 1

Standard Chemotherapy Regimen

• Sequential anthracycline and taxane-based regimen is the standard backbone for the vast majority of TNBC patients 1
• Treatment duration: 12-24 weeks (four to eight cycles) 1
• Anthracycline regimens should preferably exclude 5-FU; EC (epirubicin/cyclophosphamide) or AC (doxorubicin/cyclophosphamide) are standard 1
• All chemotherapy should be delivered preoperatively if PST is used 1

Platinum Addition

• The addition of platinum compounds (carboplatin) may be considered in triple-negative tumors and/or in patients with deleterious BRCA1/2 mutations 1
• This recommendation carries Level I, Grade C evidence, indicating moderate support 1
• Platinum compounds should not be used routinely in the adjuvant setting 1

Dose-Dense Schedules

• Consider dose-dense schedules with G-CSF support, particularly in highly proliferative tumors like TNBC 1

Surgical Management

Timing and Approach

• Surgery should follow completion of neoadjuvant chemotherapy according to general early breast cancer rules 1
• Tumor site marking must be performed if breast-conserving surgery (BCS) is anticipated 1
• Pre- and post-treatment breast MRI assessment is required (or alternative imaging modality) 1

Axillary Management

• In clinically negative axillae: sentinel lymph node biopsy (SLNB) post-PST is preferred over pre-PST 1
• In patients with baseline axillary involvement converting to negative: SLNB may be performed in selected cases, and if negative, further axillary surgery may be avoided 1
• Any tumor deposits in post-PST SLNB prompts axillary lymph node dissection (ALND) 1

Radiation Therapy

Whole-Breast Irradiation After BCS

• Postoperative radiotherapy is strongly recommended after breast-conserving surgery 1
• Boost irradiation is recommended to reduce in-breast relapse risk in patients at higher risk of local recurrence 1

Fractionation Schedule

• Moderate hypofractionation schedules (15-16 fractions of 3 Gy/fraction) are recommended for routine postoperative breast irradiation, depending on local reimbursement and equipment availability 1

Postmastectomy Radiation

• PMRT is recommended for high-risk patients including those with:
  • Involved resection margins
  • Involved axillary lymph nodes
  • T3-T4 tumors 1
• Consider PMRT in patients with one to three positive axillary lymph nodes 1

Regional Nodal Irradiation

• Comprehensive nodal irradiation is recommended for patients with involved lymph nodes 1
• After ALND, routine axillary irradiation should not be performed to the operated axilla 1

Post-Neoadjuvant Systemic Therapy

For Patients NOT Achieving pCR

This is a critical Pan-Asian contribution based on the CREATE-X trial:

• In high-risk TNBC patients not achieving pCR after standard neoadjuvant chemotherapy, add six to eight cycles of capecitabine postoperatively 1
• This recommendation is based on Asian trial data (CREATE-X) showing survival benefit 1
• Level of evidence: I, Grade C 1

For Patients Achieving pCR

• Continue standard surveillance
• No additional systemic therapy beyond what was planned is required

General Treatment Principles

Patient Selection

• All TNBC patients should receive chemotherapy, with the possible exception of low-risk "special histological subtypes" such as secretory juvenile or adenoid cystic carcinomas 1
• Treatment decisions should be based on tumor burden, biology, predicted treatment sensitivity, toxicity profile, patient age, comorbidities, and preferences 1

Timing

• Neoadjuvant systemic therapy should start as soon as diagnosis and staging is completed (ideally within 2-4 weeks) 1
• Chemotherapy should usually precede radiotherapy if both are planned 1

Bisphosphonates

• Bisphosphonates are recommended in women with low-estrogen status (postmenopausal or undergoing ovarian function suppression), especially if at high risk of relapse 1

Key Clinical Pitfalls to Avoid

1. Do not omit platinum consideration in BRCA-mutated TNBC or high-risk cases—this represents an evidence-based intensification strategy 1

2. Do not forget capecitabine for non-pCR patients—this is a Pan-Asian evidence-based recommendation that improves outcomes 1

3. Do not deliver chemotherapy split between neoadjuvant and adjuvant settings—if PST is chosen, all chemotherapy should be preoperative 1

4. Do not skip tumor marking before neoadjuvant therapy if BCS is anticipated—this is essential for surgical planning 1

5. Do not routinely use platinum in the adjuvant setting—platinum is considered only in the neoadjuvant context 1

The Pan-Asian guidelines represent 100% expert agreement across multiple Asian oncological societies (CSCO, ISMPO, JSMO, KSMO, MOS, PSMO, SSO, TOS, TSCO) and are specifically adapted to Asian patient populations while maintaining alignment with ESMO standards 1, 2.